Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02657343 · ClinicalTrials.gov registry record · Phase 1
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT02657343 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants.
The verdict
NCT02657343, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
Participants that have breast cancer that has spread to other parts of the body, is positive for a protein called HER2, and has not responded to standard treatment. This research study is a way of gaining new knowledge about the combination of Ribociclib with other drugs as a possible treatment for this diagnosis.
Interventions
- DRUG Trastuzumab
- DRUG T-DM1
- DRUG Fulvestrant
- DRUG Ribociclib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-03-09 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02657343
The ClinicalTrials.gov registry entry for NCT02657343 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Trastuzumab is the first listed.
NCT02657343 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02657343 about?
NCT02657343 is a clinical study titled "An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.". Participants that have breast cancer that has spread to other parts of the body, is positive for a protein called HER2, and has not responded to standard treatment. This research study is a way of gaining new knowledge about the combination of Ribociclib with other drugs as a possible treatment for ...
What is the current status of trial NCT02657343?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2016-03-09. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT02657343?
The interventions under investigation include: Trastuzumab (DRUG), T-DM1 (DRUG), Fulvestrant (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT02657343?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.